BlackRock Health Sciences Trust II (BMEZ) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
BlackRock Health Sciences Trust II stock (BMEZ) is currently trading at $13.81. BlackRock Health Sciences Trust II PE ratio is 5.42. BlackRock Health Sciences Trust II PS ratio (Price-to-Sales) is 8.47. WallStSmart rates BMEZ as Sell.
- BMEZ PE ratio analysis and historical PE chart
- BMEZ PS ratio (Price-to-Sales) history and trend
- BMEZ intrinsic value — DCF, Graham Number, EPV models
- BMEZ stock price prediction 2025 2026 2027 2028 2029 2030
- BMEZ fair value vs current price
- BMEZ insider transactions and insider buying
- Is BMEZ undervalued or overvalued?
- BlackRock Health Sciences Trust II financial analysis — revenue, earnings, cash flow
- BMEZ Piotroski F-Score and Altman Z-Score
- BMEZ analyst price target and Smart Rating
BlackRock Health Sciences Trust II
📊 No data available
Try selecting a different time range
BMEZ Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · BlackRock Health Sciences Trust II (BMEZ)
BMEZ is trading near its Graham intrinsic value of $17.27, suggesting the stock is reasonably priced at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
BlackRock Health Sciences Trust II (BMEZ) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around price/sales. Significant fundamental concerns warrant caution or avoidance.
BlackRock Health Sciences Trust II (BMEZ) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
BlackRock Health Sciences Trust II (BMEZ) Areas to Watch (3)
Very expensive at 8.5x annual revenue
Low institutional interest, mostly retail-driven
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
BlackRock Health Sciences Trust II (BMEZ) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 10.0/10) while 3 fall into concern territory (avg 3.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.81) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Price/Sales, Institutional Own., Market Cap. Some valuation metrics including Price/Sales (8.47) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Price/Sales and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BMEZ Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BMEZ's Price-to-Sales ratio of 8.47x trades at a deep discount to its historical average of 25.45x (0th percentile). The current valuation is 86% below its historical high of 60.04x set in Feb 2026, and 0% above its historical low of 8.47x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~60.0x as trailing revenue scaled faster than the stock price.
Insider Transactions(11 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:26:24 AM
About BlackRock Health Sciences Trust II(BMEZ)
NYSE
FINANCIAL SERVICES
ASSET MANAGEMENT
USA
BlackRock Health Sciences Trust II (BMEZ) is a closed-end fund actively managed to deliver high total returns through a diversified portfolio primarily focused on the health sciences sector, encompassing pharmaceuticals, biotechnology, and medical devices. Backed by the expertise of BlackRock, a leading global investment manager, BMEZ capitalizes on the significant growth potential and innovation trends driven by demographic changes and increased healthcare expenditures. With a disciplined investment approach, this fund represents an appealing opportunity for institutional investors seeking to capitalize on the dynamic and evolving landscape of health sciences, thereby enhancing their overall investment strategies.